Where do things stand with some players in the for-profit world of stem cell and cellular medicine companies? Here are a few brief news items with quick analysis. Mesoblast is dominating the news of late. Mesoblast reported good news from its Phase II safety trial for its mesenchymal progenitor cell (MPC) product in patients with […]
Stem Cell & Cell Med Industry Briefs Read More »
What does the future hold for the California Institute for Regenerative Medicine (CIRM), also known as the California Stem Cell Agency? While new CIRM grants should be awarded up until 2017, CIRM is rightly thinking about its future. Californians should be paying attention and thinking ahead too. You might say that since I’m a CIRM
The Case for CIRM 2.0: Continuing California’s Stem Cell Leadership Read More »
If there was one stem cell meeting I would absolutely not want to miss next month in November if at all possible, it is the 2013 World Alliance Forum “Future of Stem Cells” in San Francisco. Are you going? Win free tickets to this meeting here! Unfortunately I have a conflict so I will this
World Alliance Forum “Future of Stem Cells” features Shinya Yamanaka Read More »
The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal,
Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »
Nominations for Stem Cell Person of the Year 2013 closed last night and I ended up with a remarkable list of 30 nominees. I have included a few sentences about each one below, often taking verbiage directly from the nominator. The online voting on these nominees will start soon. The top vote getters will move
Nominations are now open for the 2013 Stem Cell Person of the Year Award. The winner receives $1,000 as well as recognition as a true difference maker and leader in the stem cell field. I found last year that all the finalists received a great deal of positive attention even if they didn’t win and
Nominations Open for 2013 Stem Cell Person of Year Award Read More »
I met with Texas Governor Rick Perry, himself a recipient of stem cell transplants, last year to talk stem cells. He was enthusiastic about stem cells to put it mildly and it was great to talk with him. My impression from meeting with him in person is that he is clearly a very intelligent, energetic,
Rick Perry Sticky Stem Cell Problem for 2016 Read More »
What would your predictions be for 7 years down the road and by the way please read the eye chart below out loud. How’s your vision? Today’s post is a chance to let one’s optimism and excitement about stem cells run a bit wild looking ahead not to next year, but 7 years ahead to
20/20 Stem Cell Predictions for the Year 2020 Read More »
IntelliCell BioSciences, Inc. of New York, a clinical stem cell establishment, has had a rough time of it lately. For example, a recent piece of bad news is that there is an impending foreclosure sale of the company’s assets. What exactly that means for the company more broadly remains unknown, but a few people tell me (take this
New FDA IntelliCell BioSciences, Audit Report: A Lot of Work to Do Read More »
IntelliCell BioSciences has had a terrible year. Well, there’s terrible and then there’s terrible! Things seem to be getting worse. For background, I detailed its troubles, ups, and downs here in a previous post. I was just working on a new draft post on the most recent, concerning FDA 483 report on the company, which I
IntelliCell Foreclosure Sale Read More »